|
1
|
Ceasovschih A, Sorodoc V, Aursulesei V, Tesloianu D, Jaba I, Petris A, Cozma CD, Mihai B, Statescu C, Lionte C, Vata L, Stoica A, Sirbu O, Tuchilus C, Anisie E, Bologa C, Haliga R, Puha G, Dumitrescu G, Constantin M, Simionov L, Obreja M, Sorodoc L. Peripheral artery disease particularities in women: a prospective study. Atherosclerosis 2020. [DOI: 10.1016/j.atherosclerosis.2020.10.519] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
|
2
|
Leleu X, Beksac M, Chou T, Dimopoulos M, Yoon S, Prince H, Chari A, Oriol A, Siegel D, Khurana M, Qi M, Obreja M, Pour L, Shelekhova T. EFFICACY AND SAFETY OF CARFILZOMIB, DEXAMETHASONE, DARATUMUMAB TWICE-WEEKLY AT 56 MG/M2 AND ONCE-WEEKLY AT 70 MG/M2 IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: CROSS-STUDY COMPARISON OF CANDOR AND MMY1001. Hematol Transfus Cell Ther 2020. [DOI: 10.1016/j.htct.2020.10.431] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
|
3
|
Quach H, Nooka A, Samoylova O, Venner C, Facon T, Spencer A, Usmani S, Weisel K, Mateos M, Kim K, Grosicki S, Suzuki K, Delimpasi S, Obreja M, Zahlten-Kumeli A. CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB VERSUS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSIS OF THE PHASE 3 CANDOR STUDY BY NUMBER OF PRIOR LINES OFTHERAPY AND PRIOR THERAPIES. Hematol Transfus Cell Ther 2020. [DOI: 10.1016/j.htct.2020.10.425] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
|
4
|
Ceasovschih A, Sorodoc V, Tesloianu D, Aursulesei V, Jaba E, Jaba I, Petris A, Cozma CD, Mihai B, Statescu C, Lionte C, Petris O, Stoica A, Sirbu O, Tuchilus C, Vata L, Bologa C, Obreja M, Alexa R, Sorodoc L. Life Quality And Psychological Gender Particularities In Patients With Peripheral Artery Disease. Atherosclerosis 2019. [DOI: 10.1016/j.atherosclerosis.2019.06.852] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
|
5
|
Hari P, Mateos MV, Abonour R, Knop S, Bensinger W, Ludwig H, Song K, Hajek R, Moreau P, Siegel DS, Feng S, Obreja M, Aggarwal SK, Iskander K, Goldschmidt H. Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes. Leukemia 2017; 31:2630-2641. [PMID: 28439109 PMCID: PMC5729352 DOI: 10.1038/leu.2017.122] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2016] [Revised: 03/09/2017] [Accepted: 04/03/2017] [Indexed: 01/12/2023]
Abstract
Autologous stem cell transplantation (ASCT) is a standard treatment for eligible multiple myeloma (MM) patients, but many patients will relapse after ASCT and require subsequent therapy. The proteasome inhibitor carfilzomib is approved for relapsed or refractory MM (RRMM). In phase 3 trials, carfilzomib-based regimens (ASPIRE, carfilzomib-lenalidomide-dexamethasone; ENDEAVOR, carfilzomib-dexamethasone) demonstrated superior progression-free survival (PFS) compared with standard therapies for RRMM (ASPIRE: lenalidomide-dexamethasone; ENDEAVOR, bortezomib-dexamethasone). This subgroup analysis of ASPIRE and ENDEAVOR evaluated outcomes according to prior ASCT status. In total, 446 patients in ASPIRE and 538 in ENDEAVOR had prior ASCT. Median PFS was longer for carfilzomib-based regimens vs non-carfilzomib-based regimens for patients with prior ASCT (ASPIRE: 26.3 vs 17.8 months (hazard ratio (HR)=0.68); ENDEAVOR: not estimable vs 10.2 months (HR=0.61)), those with one prior line of therapy that included ASCT (ASPIRE: 29.7 vs 17.8 months (HR=0.70); ENDEAVOR: not estimable vs 11.2 months (HR=0.46)), and those without prior ASCT (ASPIRE: 26.4 vs 16.6 months (HR=0.76); ENDEAVOR: 17.7 vs 8.5 months (HR=0.43)). Overall response rates also favored the carfilzomib-based regimens. No new safety signals were detected. This analysis suggests that carfilzomib-based treatment may lead to improvement in PFS and response rates regardless of prior transplant status. Further evaluation is warranted.
Collapse
Affiliation(s)
- P Hari
- Medical College of Wisconsin, Milwaukee, WI, USA
| | - M-V Mateos
- Hematology, Hospital Clinico Universitario de Salamanca-IBSAL, Salamanca, Spain
| | - R Abonour
- Indiana University Simon Cancer Center, Indianapolis, IN, USA
| | - S Knop
- Medizinische Klinik der Universitat Wurzburg, Wurzburg, Germany
| | - W Bensinger
- Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - H Ludwig
- Leukemia/Bone Marrow Transplant Program of British Columbia, Vancouver, British Columbia, Canada
| | - K Song
- University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
| | - R Hajek
- University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
| | - P Moreau
- Department of Hematology, University of Nantes, Nantes, France
| | - D S Siegel
- John Theurer Cancer Center at Hackensack University, Hackensack, NJ, USA
| | - S Feng
- Amgen Inc., Thousand Oaks, CA, USA
| | - M Obreja
- Amgen Inc., Thousand Oaks, CA, USA
| | | | | | - H Goldschmidt
- Universitatsklinikum Heidelberg, Heidelberg, Germany
| |
Collapse
|
|
6
|
Palumbo A, Stewart A, Rajkumar S, Masszi T, Spicka I, Oriol A, Hájek R, Rosiñol L, Siegel D, Mihaylov G, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak A, San-Miguel J, Ludwig H, Zojwalla N, Tonda M, Obreja M, Moreau P, Dimopoulos M. Efficacy and Safety of Carfilzomib, Lenalidomide, and Dexamethasone (KRd) vs Lenalidomide and Dexamethasone (Rd) in Patients (Pts) With Relapsed Multiple Myeloma (RMM) Based on Age: Secondary Analysis From the Phase 3 Study ASPIRE (NCT01080391). Clinical Lymphoma Myeloma and Leukemia 2015. [DOI: 10.1016/j.clml.2015.07.227] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|